Eli Lilly Hits $1 Trillion Market Cap Milestone

Eli Lilly (LLY) has officially entered the elite group of U.S. companies valued above $1 trillion, becoming the tenth American firm to reach the landmark. Shares rose 1% on Friday, reflecting strong investor confidence in the company’s expanding GLP-1 drug franchise, which continues to reshape expectations across the healthcare sector.

GLP-1 Drug Momentum Drives Investor Optimism

Lilly’s rapid ascent in market value has been powered by soaring demand for its GLP-1 treatments, part of a broader obesity-drug wave transforming both biopharma competition and long-term growth forecasts.

Not Among Seeking Alpha’s Top Healthcare Stocks

Despite the trillion-dollar milestone, Eli Lilly does not rank within Seeking Alpha’s top ten healthcare stocks under its Quant Ratings system.
LLY holds a Quant Rating of 3.47, placing it outside the upper tier.

Top Healthcare Stocks by Quant Rating

Seeking Alpha’s highest-rated healthcare companies (market cap $10B+) include:

No. 1: Guardant Health (GH) – Quant Rating: 4.95
No. 2: Incyte Corporation (INCY) – 4.93
No. 3: Pfizer (PFE) – 4.91
No. 4: Merck & Co. (MRK) – 4.87
No. 5: Roivant Sciences (ROIV) – 4.82
No. 6: Vertex Pharmaceuticals (VRTX) – 4.70
No. 7: Astellas Pharma (ALPMY) – 4.69
No. 8: Illumina (ILMN) – 4.62
No. 9: Neurocrine Biosciences (NBIX) – 4.58
No. 10: Exelixis (EXEL) – 4.58

ETF Options for Sector-Wide Exposure

Investors seeking diversified healthcare exposure can consider ETFs such as:
XLV, VHT, IHI, IXJ, IYH, FHLC, FXH, IBB, XBI, FBT, BBH, PBE, IDNA, ARKG, GNOM, BIB, HELX.